Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

In this case report, an 80-year-old woman experienced elevated alkaline phosphatase levels due to the use of Viviscal hair supplements. Her levels returned to normal after discontinuing the supplement, highlighting the need for clinicians to consider supplements as potential causes of abnormal lab results.

In this study, 27 pediatric patients with alopecia areata treated with methotrexate showed statistically significant improvement in hair regrowth between 12-15 months, suggesting the medication's delayed but effective results, though common side effects included mood changes and gastrointestinal discomfort.

In this reported case of SAPHO syndrome, methotrexate treatment led to significant clinical improvement after other treatments for skin lesions and arthritis proved less effective.

This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

This study reported that treatment with cyproterone acetate alone and then with incremental estrogen doses induced mild feminizing effects in late-pubertal trans-girls, with further feminization observed after adding estrogen.

This study found that treatment with oral contraceptives containing 35mg ethinylestradiol and 2mg cyproterone acetate significantly reduced serum AMH levels in women with clomiphene citrate-resistant polycystic ovary syndrome, unlike metformin.

This study found that finasteride effectively prevented testosterone-induced kidney stone formation in renal tubular cells by reducing COM crystal adhesion and crystallization.

This study found that topical fulvestrant did not significantly improve hair growth parameters in men and postmenopausal women with androgenetic alopecia, unlike minoxidil, which was more effective in men.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.

In this study, MMF plus prednisolone was found to induce remission in 81% of patients with proliferative lupus nephritis, with fewer adverse effects such as alopecia and amenorrhea compared to CYC plus prednisolone, despite similar overall remission rates.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

This study found that combined treatment with anastrozole and cyproterone acetate improved the adult height prognosis in testotoxicosis, as observed in two brothers, with good tolerance reported.

Long-term use of finasteride may cause breast cancer in men.

This report details two cases of accelerated hair loss potentially related to 5-aminosalicylic acid enema therapy in patients with ulcerative proctitis.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.

This study observed that women using combined oral contraceptives experienced more nausea, vomiting, and hair loss, while those on Depo-Provera were more likely to gain weight.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

This meeting review discusses recent advances in systemic psoriasis treatments, emphasizing the impact of dimethylfumarate monotherapy on understanding psoriasis and treatment strategies; it reports no new clinical results.